Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Halank

Showing results (91-100 of 133) with videos related to

Pageof 14
Sort By:
The European Respiratory Journal|February 11, 2012
Safety and efficacy of exercise training in various forms of pulmonary hypertensionEkkehard Grünig, Mona Lichtblau, Nicola Ehlken, et al.
Circulation|September 20, 2006
Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertensionDerliz Mereles, Nicola Ehlken, Sandra Kreuscher, et al.
Circulation|March 17, 2025
Correction to: Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 StudyMarius M Hoeper, Britta Oerke, Max Wissmüller, et al.
International Journal of Cardiology|September 8, 2018
Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension: Updated recommendations from the Cologne Consensus Conference 2018Karen M Olsson, Michael Halank, Benjamin Egenlauf, et al.
Pulmonary Circulation|May 4, 2022
An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertensionMarc A Simon, Kate Hanrott, David C Budd, et al.
Circulation|June 28, 2024
Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 StudyMarius M Hoeper, Britta Oerke, Max Wissmüller, et al.
Pneumologie (Stuttgart, Germany)|October 6, 2025
[Treatment Algorithm of Pulmonary Arterial Hypertension]Ekkehard Grünig, Katrin Milger, Albert Omlor, et al.
ERJ Open Research|January 21, 2026
Safety and efficacy of upfront triple therapy including parenteral treprostinil compared to double oral therapy in PAH (TripleTRE): study protocol for a randomised trialOlivier Sitbon, Gergely Agoston, Roberto Badagliacca, et al.
International Journal of Cardiology|January 7, 2012
Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011Marius M Hoeper, Stefan Andreas, Andreas Bastian, et al.
Blood Advances|July 26, 2021
A targeted proteomics investigation of the obesity paradox in venous thromboembolismVincent Ten Cate, Thomas Koeck, Jürgen Prochaska, et al.
Pageof 14

Showing results (91-100 of 133) with videos related to

Sort By:
Pageof 14
The European Respiratory Journal|February 11, 2012
Safety and efficacy of exercise training in various forms of pulmonary hypertensionEkkehard Grünig, Mona Lichtblau, Nicola Ehlken, et al.
Circulation|September 20, 2006
Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertensionDerliz Mereles, Nicola Ehlken, Sandra Kreuscher, et al.
Circulation|March 17, 2025
Correction to: Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 StudyMarius M Hoeper, Britta Oerke, Max Wissmüller, et al.
International Journal of Cardiology|September 8, 2018
Decompensated right heart failure, intensive care and perioperative management in patients with pulmonary hypertension: Updated recommendations from the Cologne Consensus Conference 2018Karen M Olsson, Michael Halank, Benjamin Egenlauf, et al.
Pulmonary Circulation|May 4, 2022
An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertensionMarc A Simon, Kate Hanrott, David C Budd, et al.
Circulation|June 28, 2024
Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 StudyMarius M Hoeper, Britta Oerke, Max Wissmüller, et al.
Pneumologie (Stuttgart, Germany)|October 6, 2025
[Treatment Algorithm of Pulmonary Arterial Hypertension]Ekkehard Grünig, Katrin Milger, Albert Omlor, et al.
ERJ Open Research|January 21, 2026
Safety and efficacy of upfront triple therapy including parenteral treprostinil compared to double oral therapy in PAH (TripleTRE): study protocol for a randomised trialOlivier Sitbon, Gergely Agoston, Roberto Badagliacca, et al.
International Journal of Cardiology|January 7, 2012
Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011Marius M Hoeper, Stefan Andreas, Andreas Bastian, et al.
Blood Advances|July 26, 2021
A targeted proteomics investigation of the obesity paradox in venous thromboembolismVincent Ten Cate, Thomas Koeck, Jürgen Prochaska, et al.
Pageof 14